Praxa Sense secures investment round: Certified remote patient monitoring within reach

Liselotte StolkFunding

Delft, July 2023 – The Dutch MedTech startup Praxa Sense, a company with leading solutions in remote patient monitoring, successfully secured an investment round to enter the commercialisation phase. This round is led by business angel investor Arthur Oudshoorn together with a group of informal investors. Arthur is an experienced Entrepreneur with a proven track record in the biotech market. The benefits Praxa’s revolutionary technology brings to the healthcare market triggered his interest;”The breakthrough technology that Praxa Sense is providing to the healthcare market will be a game-changer in remote patient care. The enthusiasm with which the product has been received by patients during trials has exceeded all our expectations. I am proud to contribute to this “all Dutch” innovation in healthcare.” Praxa Sense, founded in 2018 by Leonard Moonen and Liselotte Stolk, initially focused on the early detection of atrial fibrillation. During the covid-crisis the solution was extended to reliably monitor a variety of patients’ vital signs (heart rate, blood saturation, temperature, movement). Simultaneously a revolutionary new sensor is developed in collaboration with the Delft University of Technology, Fraunhofer and … Lees meer

Eurostars #1: Praxa Sense’s AMBULAS project

Liselotte StolkSubsidies

Praxa Sense is proud to announce its success in the most recent Eurostars round, where we ranked number 1 out of all 428 applications in Europe. With the AMBULAS project we will further develop our sensor system, the most accurate remote monitoring device for continuous passive measurements in an ambulant environment of (among others) ECG, blood oxygen saturation, temperature and movement. The combination of these measurements are highly valued in remote monitoring in multiple care paths.   During this project an additional revolutionary sensor will be developed that overcomes problems of inaccuracy due to motion sensitivity, one of the biggest obstacles in reliable remote monitoring. Thus, the device can provide relief to an overburdened healthcare system, while delivering regular and accurate readings that require minimal involvement from the patient.  We are proud of our collaboration with Catalyze, AdviCo Microelectronics and Fraunhofer Institute for Microelectronic Circuits and Systems n the development of this top-of-class Eurostars proposal and look forward to the partnership with our new international partners.  About Eurostars  Eurostars is a European innovation program and an initiative of EUREKA and the … Lees meer

FME “Patiënten met hartritmestoornis thuis slim gemonitord”

Liselotte StolkArticle

Afi is een apparaatje met verschillende sensoren dat op afstand de gezondheid van mensen met hartritmestoornissen slim en langer kan monitoren. Het apparaat wordt op het borstbeen geplakt met een sticker en kan personen tot wel 30 dagen monitoren. Mensen kunnen zo eenvoudig gemonitord worden, zonder dat zij hiervoor naar het ziekenhuis moeten. Met Afi kan het hartritme van een persoon tot 30 dagen in de gaten gehouden worden. De huidige monitoringsapparatuur kan dit slechts 24 tot 48 uur. Op deze manier kan nu sneller en beter herkend worden of iemand last heeft van ‘boezemfibrilleren’. Lees het hele artikel hier:

Afi featured in MT Integraal [Dutch article]

Liselotte StolkArticle

Een Gat Tussen AI en de Klinische Praktijk? […]”Praxa Sense (YESDelft!, Delft, Nederland) werkt bijvoorbeeld aan de ontwikkeling van Afi. Deze meet een ecg-signaal en bevat daarnaast een PPG-sensor, een bewegingssensor en temperatuurmeter. Extra metingen resulteren echter in meer variabelen die beoordeeld moeten worden. Een algoritme dat met behulp van AI naast het ECG-signaal ook deze variabelen meeneemt in AF detectie maakt dit klinisch toepasbaar voor langdurige metingen, omdat een arts of ECG-analist zelf minder handmatig moet controleren. Een nog breder algoritme dat naast ECG-, temperatuur- en PPG-data ook relevante klinische gegevens als leeftijd en BMI van de patiënt meeneemt, maakt een voorspelling door het algoritme nog patiënt-specifieker. Wanneer alle parameters voor een maand gemeten worden, is dit klinisch alleen relevant indien het automatisch geannoteerd en geanalyseerd kan worden. Een device als Afi en een achterliggend algoritme voor langdurige metingen, biedt een ondersteunende functie voor de uiteindelijke klinische diagnose.”

Praxa Sense part of batch #1 Techleap’s Pole Position

Liselotte StolkProgrammes

Pole Position Batch #1: Meet the 10 selected deeptech companies Techleap is on a mission to connect and empower startups to grow and sustain a productive tech community. They do this by utilizing a founder-centric approac. Therefore, we are very proud and happy to announce that Praxa Sense has been selected to be part of the first ‘Pole Position’ batch, organized by Techleap. Pole Position is a new, exclusive initiative aimed at facilitating deeptech startups’ growth. The first batch will focus on helping 10 ambitious deeptech companies within the medical field to reach the scaleup growth phase by providing tailored scaling knowledge from experts as well as facilitating peer-to-peer learning between participants. Found out more by following this link:

First Clinical Trial at Reinier de Graaf Hospital has started

Liselotte StolkTrials

The first clinical trial with Afi has started in August 2021 at the Reinier de Graaf Hospital in Delft. In this study people who undergo an electrocardioversion are included. Electrocardioversion is a treatment which is used for people who suffer from ‘atrial fibrillation’, which makes this group very suitable for data collection on this arrhythmia. With the gathered data, Praxa Sense is training and validating its top-of-class Machine Learning algorithm that can be used for automatic diagnosis with minimal required effort of a healthcare professional, which will further unburden healthcare. During the trial, 165 patients will be included. The results will be shared in a paper. Stay tuned!

Praxa Sense participates in ZorgTech program to validate Afi

Praxa Sense Website AdminSubsidies

The ZorgTech program is a collaboration between Innovation Quarter, MRDH, TNO, Medical Delta and the province of Zuid-Holland which supports innovations. Praxa Sense participates in the ZorgTech program to validate and implement Afi which is a user-friendly health monitor that can be used at home. We are now focused on monitoring and detecting heart rhythm disorders. Within the ZorgTech program, Afi will be tested in clinical practice and medically approved in a clinical research study at Reinier de Graaf Gasthuis. Innovation Quarter visited our office for an interview with Leonard Moonen and the cardiologist Jan Constandse who performs research with Afi. You can read the full Dutch article here:

Praxa Sense received ZonMW Subsidy

Liselotte StolkFunding

zonmw subsidy video

Praxa Sense received ZonMW subsidy Praxa Sense received €15.000 from ZonMW to transform Afi into a home monitoring device for COVID-19 patients. With this subsidy, Praxa Sense can add oxygen saturation (SpO2) sensors to Afi. Oxygen saturation is a vital parameter that indicates the blood’s oxygen level. Oxygen saturation Praxa Sense develops Afi, a medical multi-sensor system that can detect heart rhythm disorders early by continuous monitoring. Afi monitors heart rate, respiratory rate, ECG and patient activity with an ECG, PPG- and IMU sensor. The PPG-sensor will be adjusted to enable monitoring oxygen saturation as well. Praxa Sense received ZonMW subsidy to complete this project. Within the ZonMW project, the oxygen saturation sensor be developed, validated and manufactured. ZonMW video Leonard Moonen (CEO) and Muriël van Oers (Clinical Research Coordinator), were invited to join a video production of ZonMW. Click here to watch the video. Read more Read more about Afi on our Product page or Contact Us.